Treatment of neurological deficits in the striatum or substanta nigra pars compacta
    16.
    发明授权
    Treatment of neurological deficits in the striatum or substanta nigra pars compacta 有权
    治疗纹状体或黑质神经功能缺损

    公开(公告)号:US08846394B2

    公开(公告)日:2014-09-30

    申请号:US12268647

    申请日:2008-11-11

    IPC分类号: C12N5/07 A61K38/18 A61K38/17

    摘要: The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering human recombinant GDF5 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the capacity to differentiate towards a dopaminergic phenotype to in fact differentiate towards a dopaminergic phenotype, and to neurotrophic compositions and matrices suitable for use in such treatments.

    摘要翻译: 本发明涉及通过以有效诱导细胞群的量将人重组GDF5给予人纹状体或黑质成分的方式来治疗对纹状体或黑质成分的损伤或疾病产生的神经功能缺损的方法 具有分化为多巴胺能表型的能力,实际上分化为多巴胺能表型,以及适用于这种治疗的神经营养组合物和基质。

    Treatment of Neurological Deficits in the Striatum or Substanta Nigra Pars Compacta
    18.
    发明申请
    Treatment of Neurological Deficits in the Striatum or Substanta Nigra Pars Compacta 审中-公开
    治疗纹状体或大脑黑质颗粒中的神经缺陷

    公开(公告)号:US20080254538A1

    公开(公告)日:2008-10-16

    申请号:US12098690

    申请日:2008-04-07

    IPC分类号: C12N5/06

    摘要: The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering BMP7 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the capacity to differentiate towards a dopaminergic phenotype to in fact differentiate towards a dopaminergic phenotype, and to neurotrophic compositions and matrices suitable for use in such treatments.

    摘要翻译: 本发明涉及通过将BMP7施用于人的纹状体或黑质块状物,以有效诱导具有该细胞群的细胞群的量,将治疗由纹状体或黑质致密结构引起的损伤或疾病的神经功能缺损 区分多巴胺能表型的能力实际上分化为多巴胺能表型,以及适合用于这种治疗的神经营养组合物和基质。

    TREATMENT OF NEUROLOGICAL DEFICITS IN THE STRIATUM OR SUBSTANTA NIGRA PARS COMPACTA
    19.
    发明申请
    TREATMENT OF NEUROLOGICAL DEFICITS IN THE STRIATUM OR SUBSTANTA NIGRA PARS COMPACTA 有权
    治疗STRIATUM或SUBSTANTA NIGRA PARS COMPACTA中的神经缺陷

    公开(公告)号:US20090149371A1

    公开(公告)日:2009-06-11

    申请号:US12268647

    申请日:2008-11-11

    IPC分类号: A61K38/18

    摘要: The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering human recombinant GDF5 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the capacity to differentiate towards a dopaminergic phenotype to in fact differentiate towards a dopaminergic phenotype, and to neurotrophic compositions and matrices suitable for use in such treatments.

    摘要翻译: 本发明涉及通过以有效诱导细胞群的量将人重组GDF5给予人纹状体或黑质成分的方式来治疗对纹状体或黑质成分的损伤或疾病产生的神经功能缺损的方法 具有分化为多巴胺能表型的能力,实际上分化为多巴胺能表型,以及适用于这种治疗的神经营养组合物和基质。